{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T06:52:12Z","timestamp":1793256732460,"version":"4.5.0"},"reference-count":267,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000866","name":"Cardiff University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000866","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ageing Research Reviews"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.arr.2023.101979","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T19:09:54Z","timestamp":1686856194000},"page":"101979","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":176,"special_numbering":"C","title":["Antidiabetic agents as a novel treatment for Alzheimer\u2019s and Parkinson\u2019s disease"],"prefix":"10.1016","volume":"89","author":[{"given":"Joseph","family":"Nowell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Blunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhruv","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6551-2002","authenticated-orcid":false,"given":"Paul","family":"Edison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arr.2023.101979_bib1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrneurol.2011.189","article-title":"Depression in Parkinson disease--epidemiology, mechanisms and management","volume":"8","author":"Aarsland","year":"2011","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.arr.2023.101979_bib2","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/jnc.13087","article-title":"Neuroprotective effects of vildagliptin in rat rotenone Parkinson's disease model: role of RAGE-NFkappaB and Nrf2-antioxidant signaling pathways","volume":"133","author":"Abdelsalam","year":"2015","journal-title":"J. Neurochem"},{"key":"10.1016\/j.arr.2023.101979_bib3","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.neurobiolaging.2013.10.076","article-title":"Neuroprotective effects of the amylin analogue pramlintide on Alzheimer's disease pathogenesis and cognition","volume":"35","author":"Adler","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.arr.2023.101979_bib4","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.cmet.2019.07.013","article-title":"Glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus regulate food intake","volume":"30","author":"Adriaenssens","year":"2019","journal-title":"Cell Metab."},{"key":"10.1016\/j.arr.2023.101979_bib5","unstructured":"Alzheimer's Disease International, 2018. World Alzheimer Report 2018: The state of the art of dementia research: New frontiers. Alzheimer's Disease International, London."},{"key":"10.1016\/j.arr.2023.101979_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2019.111932","article-title":"Exenatide alleviates mitochondrial dysfunction and cognitive impairment in the 5xFAD mouse model of Alzheimer's disease","volume":"370","author":"An","year":"2019","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.arr.2023.101979_bib7","doi-asserted-by":"crossref","first-page":"255","DOI":"10.21037\/atm.2018.04.41","article-title":"DPP-4 inhibitors: a promising therapeutic approach against Alzheimer's disease","volume":"6","author":"Angelopoulou","year":"2018","journal-title":"Ann. Transl. Med"},{"key":"10.1016\/j.arr.2023.101979_bib8","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrneurol.2017.185","article-title":"Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums","volume":"14","author":"Arnold","year":"2018","journal-title":"Nat. Rev. Neurol."},{"issue":"Suppl 1","key":"10.1016\/j.arr.2023.101979_bib9","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/dom.13162","article-title":"A review of GLP-1 receptor agonists: evolution and advancement, through the lens of randomised controlled trials","volume":"20","author":"Aroda","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.arr.2023.101979_bib10","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/ana.25826","article-title":"Brain insulin signaling, alzheimer disease pathology, and cognitive function","volume":"88","author":"Arvanitakis","year":"2020","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.arr.2023.101979_bib11","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.arr.2023.101979_bib12","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1001\/jamaneurol.2018.4304","article-title":"Utility of neuronal-derived exosomes to examine molecular mechanisms that affect motor function in patients with parkinson disease: a secondary analysis of the exenatide-PD trial","volume":"76","author":"Athauda","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.arr.2023.101979_bib13","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/ejn.14096","article-title":"Post hoc analysis of the Exenatide-PD trial-Factors that predict response","volume":"49","author":"Athauda","year":"2019","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.arr.2023.101979_bib14","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1007\/s00415-018-8768-0","article-title":"Intranasal insulin in Alzheimer's dementia or mild cognitive impairment: a systematic review","volume":"265","author":"Avgerinos","year":"2018","journal-title":"J. Neurol."},{"key":"10.1016\/j.arr.2023.101979_bib15","first-page":"11","article-title":"Empagliflozin induced ketosis, upregulated IGF-1\/insulin receptors and the canonical insulin signaling pathway in neurons, and decreased the excitatory neurotransmitter glutamate in the brain of non-diabetics","author":"Avgerinos","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.arr.2023.101979_bib16","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1172\/JCI68295","article-title":"Exenatide and the treatment of patients with Parkinson's disease","volume":"123","author":"Aviles-Olmos","year":"2013","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.arr.2023.101979_bib17","first-page":"337","article-title":"Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease","volume":"4","author":"Aviles-Olmos","year":"2014","journal-title":"J. Park. Dis."},{"key":"10.1016\/j.arr.2023.101979_bib18","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1002\/mds.28181","article-title":"Insulin sensitivity in de novo parkinson's disease: a hyperinsulinemic-euglycemic clamp study","volume":"35","author":"Aziz","year":"2020","journal-title":"Mov. Disord."},{"key":"10.1016\/j.arr.2023.101979_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/alz.042909","article-title":"Liraglutide and semaglutide: Pooled post hoc analysis to evaluate risk of dementia in patients with type 2 diabetes","volume":"16","author":"Ballard","year":"2020","journal-title":"Alzheimer'S. Dement."},{"key":"10.1016\/j.arr.2023.101979_bib20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ejphar.2004.02.040","article-title":"The source of cerebral insulin","volume":"490","author":"Banks","year":"2004","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.arr.2023.101979_bib21","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.pharmthera.2012.07.006","article-title":"Insulin in the brain: there and back again","volume":"136","author":"Banks","year":"2012","journal-title":"Pharm. Ther."},{"key":"10.1016\/j.arr.2023.101979_bib22","article-title":"Impaired brain insulin signalling in Parkinson's disease","author":"Bassil","year":"2021","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.arr.2023.101979_bib23","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/path.5056","article-title":"The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease","volume":"245","author":"Batista","year":"2018","journal-title":"J. Pathol."},{"key":"10.1016\/j.arr.2023.101979_bib24","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/jnr.21483","article-title":"Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease","volume":"86","author":"Bertilsson","year":"2008","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.arr.2023.101979_bib25","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.neurobiolaging.2006.06.017","article-title":"Positive association between risk for late-onset Alzheimer disease and genetic variation in IDE","volume":"28","author":"Bjork","year":"2007","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.arr.2023.101979_bib26","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3389\/fendo.2014.00161","article-title":"Insulin in the brain: its pathophysiological implications for States related with central insulin resistance, type 2 diabetes and Alzheimer's disease","volume":"5","author":"Blazquez","year":"2014","journal-title":"Front Endocrinol. (Lausanne)"},{"key":"10.1016\/j.arr.2023.101979_bib27","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1172\/JCI57256","article-title":"An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer\u2019s disease\u2013associated A\u03b2 oligomers","volume":"122","author":"Bomfim","year":"2012","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.arr.2023.101979_bib28","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/jnc.12380","article-title":"Dysregulation of leptin signaling in Alzheimer disease: evidence for neuronal leptin resistance","volume":"128","author":"Bonda","year":"2014","journal-title":"J. Neurochem."},{"key":"10.1016\/j.arr.2023.101979_bib29","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1093\/brain\/awaa262","article-title":"Diabetes medications and risk of Parkinson's disease: a cohort study of patients with diabetes","volume":"143","author":"Brauer","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.arr.2023.101979_bib30","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00702-010-0456-x","article-title":"Cerebrospinal fluid insulin during non-neurological surgery","volume":"117","author":"Bromander","year":"2010","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.arr.2023.101979_bib31","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0168-8227(01)00266-2","article-title":"Dementia and its associations in type 2 diabetes mellitus: The Fremantle Diabetes Study","volume":"53","author":"Bruce","year":"2001","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.arr.2023.101979_bib32","doi-asserted-by":"crossref","unstructured":"Bunn, F., Burn, A.M., Goodman, C., Robinson, L., Rait, G., Norton, S., Bennett, H., Poole, M., Schoeman, J., Brayne, C., 2016. Comorbidity and dementia: a mixed-method study on improving health care for people with dementia (CoDem), Southampton (UK).","DOI":"10.3310\/hsdr04080"},{"key":"10.1016\/j.arr.2023.101979_bib33","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.trci.2019.09.010","article-title":"The TOMMORROW study: design of an Alzheimer's disease delay-of-onset clinical trial","volume":"5","author":"Burns","year":"2019","journal-title":"Alzheimers Dement (N. Y)"},{"key":"10.1016\/j.arr.2023.101979_bib34","doi-asserted-by":"crossref","DOI":"10.3233\/JAD-210256","article-title":"A GLP-1\/GIP dual receptor agonist DA4-JC effectively attenuates cognitive impairment and pathology in the APP\/PS1\/Tau model of Alzheimer's disease","author":"Cai","year":"2021","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2023.101979_bib35","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s40263-015-0301-8","article-title":"Novel GLP-1 (Glucagon-Like Peptide-1) analogues and insulin in the treatment for Alzheimer's disease and other Neurodegenerative diseases","volume":"29","author":"Calsolaro","year":"2015","journal-title":"CNS Drugs"},{"key":"10.1016\/j.arr.2023.101979_bib36","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.11124\/JBISRIR-2017-003380","article-title":"Metformin and Alzheimer's disease, dementia and cognitive impairment: a systematic review protocol","volume":"15","author":"Campbell","year":"2017","journal-title":"JBI Database Syst. Rev. Implement Rep."},{"key":"10.1016\/j.arr.2023.101979_bib37","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/WNR.0000000000000548","article-title":"A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson's disease by reducing chronic inflammation in the brain","volume":"27","author":"Cao","year":"2016","journal-title":"Neuroreport"},{"key":"10.1016\/j.arr.2023.101979_bib38","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejphar.2018.03.024","article-title":"DA5-CH, a novel GLP-1\/GIP dual agonist, effectively ameliorates the cognitive impairments and pathology in the APP\/PS1 mouse model of Alzheimer's disease","volume":"827","author":"Cao","year":"2018","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.arr.2023.101979_bib39","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3389\/fendo.2013.00073","article-title":"Beyond glycemic control in diabetes mellitus: effects of incretin-based therapies on bone metabolism","volume":"4","author":"Ceccarelli","year":"2013","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.arr.2023.101979_bib40","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1212\/WNL.0b013e3182553cc9","article-title":"Clinical features of Parkinson disease when onset of diabetes came first: a case-control study","volume":"78","author":"Cereda","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2023.101979_bib41","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3233\/JAD-190864","article-title":"An exploratory phase IIa study of the PPAR delta\/gamma agonist T3D-959 assessing metabolic and cognitive function in subjects with mild to moderate Alzheimer's disease","volume":"73","author":"Chamberlain","year":"2020","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2023.101979_bib42","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jocn.2020.09.054","article-title":"Semaglutide-mediated protection against Abeta correlated with enhancement of autophagy and inhibition of apotosis","volume":"81","author":"Chang","year":"2020","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.arr.2023.101979_bib43","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/aps.2017.28","article-title":"Amyloid beta: structure, biology and structure-based therapeutic development","volume":"38","author":"Chen","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.arr.2023.101979_bib44","doi-asserted-by":"crossref","first-page":"10722","DOI":"10.1038\/s41598-018-28449-z","article-title":"Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease","volume":"8","author":"Chen","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.arr.2023.101979_bib45","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jdiacomp.2017.01.006","article-title":"Effects of pioglitazone on the incidence of dementia in patients with diabetes","volume":"31","author":"Chou","year":"2017","journal-title":"J. Diabetes Complicat."},{"key":"10.1016\/j.arr.2023.101979_bib46","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.parkreldis.2018.08.023","article-title":"Detrimental effect of type 2 diabetes mellitus in a large case series of Parkinson's disease","volume":"64","author":"Chung","year":"2019","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.arr.2023.101979_bib47","doi-asserted-by":"crossref","first-page":"897","DOI":"10.3233\/JAD-141791","article-title":"Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia","volume":"44","author":"Claxton","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2023.101979_bib48","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1474-4422(18)30403-4","article-title":"Global, regional, and national burden of Alzheimer's disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"Collaborators","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.arr.2023.101979_bib49","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","article-title":"Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"Collaborators","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.arr.2023.101979_bib50","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/archneurol.2011.233","article-title":"Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial","volume":"69","author":"Craft","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.arr.2023.101979_bib51","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3233\/JAD-161256","article-title":"Effects of regular and long-acting insulin on cognition and alzheimer's disease biomarkers: a pilot clinical trial","volume":"57","author":"Craft","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2023.101979_bib52","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2020.1840","article-title":"Safety, efficacy, and feasibility of intranasal insulin for the treatment of mild cognitive impairment and alzheimer disease dementia: a randomized clinical trial","author":"Craft","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.arr.2023.101979_bib53","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S1474-4422(20)30173-3","article-title":"Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial","volume":"19","author":"Cukierman-Yaffe","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.arr.2023.101979_bib54","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1148\/radiol.2503080751","article-title":"Mild cognitive impairment and alzheimer disease: patterns of altered cerebral blood flow at MR imaging","volume":"250","author":"Dai","year":"2009","journal-title":"Radiology"},{"key":"10.1016\/j.arr.2023.101979_bib55","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2337\/dbi18-0045","article-title":"Glucagon-like peptide 1 in the brain: where is it coming from, where is it going?","volume":"68","author":"Daniels","year":"2019","journal-title":"Diabetes"},{"key":"10.1016\/j.arr.2023.101979_bib56","unstructured":"De Meyts, P., 2000. The Insulin Receptor and Its Signal Transduction Network, in: Feingold, K.R., Anawalt, B., Boyce, A., Chrousos, G., de Herder, W.W., Dhatariya, K., Dungan, K., Hershman, J.M., Hofland, J., Kalra, S., Kaltsas, G., Koch, C., Kopp, P., Korbonits, M., Kovacs, C.S., Kuohung, W., Laferrere, B., Levy, M., McGee, E.A., McLachlan, R., Morley, J.E., New, M., Purnell, J., Sahay, R., Singer, F., Sperling, M.A., Stratakis, C.A., Trence, D.L., Wilson, D.P. (Eds.), Endotext, South Dartmouth (MA)."},{"key":"10.1016\/j.arr.2023.101979_bib57","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.neurobiolaging.2012.08.003","article-title":"Leptin prevents hippocampal synaptic disruption and neuronal cell death induced by amyloid \u03b2","author":"Doherty","year":"2013","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.arr.2023.101979_bib58","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0065-1281(82)80080-9","article-title":"C-peptide immunoreactive neurons in human brain","volume":"70","author":"Dorn","year":"1982","journal-title":"Acta Histochem"},{"key":"10.1016\/j.arr.2023.101979_bib59","first-page":"21","article-title":"Liraglutide protects against brain amyloid-beta1-42 accumulation in female mice with early Alzheimer's disease-like pathology by partially rescuing oxidative\/nitrosative stress and inflammation","author":"Duarte","year":"2020","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.arr.2023.101979_bib60","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.neuroscience.2012.10.045","article-title":"The incretin analogue D-Ala2GIP reduces plaque load, astrogliosis and oxidative stress in an APP\/PS1 mouse model of Alzheimer's disease","volume":"228","author":"Duffy","year":"2013","journal-title":"Neuroscience"},{"key":"10.1016\/j.arr.2023.101979_bib61","doi-asserted-by":"crossref","first-page":"6274","DOI":"10.1038\/s41598-019-42770-1","article-title":"Role of adipose tissue GLP-1R expression in metabolic improvement after bariatric surgery in patients with type 2 diabetes","volume":"9","author":"Ejarque","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.arr.2023.101979_bib62","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/msj.20159","article-title":"Transgenic mouse models of Alzheimer's disease","volume":"77","author":"Elder","year":"2010","journal-title":"Mt Sinai J. Med"},{"key":"10.1016\/j.arr.2023.101979_bib63","doi-asserted-by":"crossref","first-page":"246","DOI":"10.2174\/1568026619666190201152153","article-title":"PTP1b inhibition, a promising approach for the treatment of diabetes type II","volume":"19","author":"Eleftheriou","year":"2019","journal-title":"Curr. Top. Med Chem."},{"key":"10.1016\/j.arr.2023.101979_bib64","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/bs.irn.2020.03.018","article-title":"A role for sodium glucose cotransporter 2 inhibitors (SGLT2is) in the treatment of Alzheimer's disease?","volume":"155","author":"Esterline","year":"2020","journal-title":"Int Rev. Neurobiol."},{"key":"10.1016\/j.arr.2023.101979_bib65","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3233\/JAD-121888","article-title":"D-Ala2GIP facilitated synaptic plasticity and reduces plaque load in aged wild type mice and in an Alzheimer's disease mouse model","volume":"35","author":"Faivre","year":"2013","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2023.101979_bib66","article-title":"Rapid transport of insulin to the brain following intranasal administration in rats","volume":"14","author":"Fan","year":"2019","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.arr.2023.101979_bib67","doi-asserted-by":"crossref","DOI":"10.3233\/JAD-181240","article-title":"Metformin improves learning and memory in the SAMP8 mouse model of Alzheimer's disease","volume":"68","author":"Farr","year":"2019","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2023.101979_bib68","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1073\/pnas.0230450100","article-title":"Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo","volume":"100","author":"Farris","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.arr.2023.101979_bib69","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13063-019-3259-x","article-title":"Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study)","volume":"20","author":"Femminella","year":"2019","journal-title":"Trials"},{"key":"10.1016\/j.arr.2023.101979_bib70","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.neuropharm.2018.02.012","article-title":"Two novel dual GLP-1\/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease","volume":"133","author":"Feng","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.arr.2023.101979_bib71","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3389\/fnins.2018.00830","article-title":"Insulin resistance in Alzheimer's disease","volume":"12","author":"Ferreira","year":"2018","journal-title":"Front Neurosci."},{"key":"10.1016\/j.arr.2023.101979_bib72","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1096\/fj.04-2572com","article-title":"Obesity-related leptin regulates Alzheimer's Abeta","volume":"18","author":"Fewlass","year":"2004","journal-title":"Faseb J."},{"key":"10.1016\/j.arr.2023.101979_bib73","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3389\/fnins.2019.00868","article-title":"The relevance of insulin action in the dopaminergic system","volume":"13","author":"Fiory","year":"2019","journal-title":"Front Neurosci."},{"key":"10.1016\/j.arr.2023.101979_bib74","first-page":"5","article-title":"Semaglutide lowers body weight in rodents via distributed neural pathways","author":"Gabery","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.arr.2023.101979_bib75","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.it.2008.05.002","article-title":"Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression","volume":"29","author":"Gao","year":"2008","journal-title":"Trends Immunol."},{"key":"10.1016\/j.arr.2023.101979_bib76","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.neuint.2019.04.006","article-title":"Exendin-4 attenuates brain mitochondrial toxicity through PI3K\/Akt-dependent pathway in amyloid beta (1-42)-induced cognitive deficit rats","volume":"128","author":"Garabadu","year":"2019","journal-title":"Neurochem Int"},{"key":"10.1016\/j.arr.2023.101979_bib77","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13041-015-0138-6","article-title":"Insulin and IGF1 signalling pathways in human astrocytes in vitro and in vivo; characterisation, subcellular localisation and modulation of the receptors","volume":"8","author":"Garwood","year":"2015","journal-title":"Mol. Brain"},{"key":"10.1016\/j.arr.2023.101979_bib78","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.peptides.2017.11.017","article-title":"GLP-1 receptor agonists show neuroprotective effects in animal models of diabetes","volume":"100","author":"Gault","year":"2018","journal-title":"Peptides"},{"key":"10.1016\/j.arr.2023.101979_bib79","first-page":"877","article-title":"Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"16","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.arr.2023.101979_bib80","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.regpep.2006.06.004","article-title":"Role of endogenous amylin in glucagon secretion and gastric emptying in rats demonstrated with the selective antagonist, AC187","volume":"137","author":"Gedulin","year":"2006","journal-title":"Regul. Pept."},{"key":"10.1016\/j.arr.2023.101979_bib81","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3389\/fnagi.2016.00108","article-title":"In Alzheimer's disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial","volume":"8","author":"Gejl","year":"2016","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.arr.2023.101979_bib82","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.arr.2023.101979_bib83","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3389\/fendo.2020.00178","article-title":"GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: review of head-to-head clinical trials","volume":"11","author":"Gilbert","year":"2020","journal-title":"Front Endocrinol."},{"key":"10.1016\/j.arr.2023.101979_bib84","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40266-021-00853-7","article-title":"The future of incretin-based approaches for neurodegenerative diseases in older adults: which to choose? A review of their potential efficacy and suitability","volume":"38","author":"Girges","year":"2021","journal-title":"Drugs Aging"},{"key":"10.1016\/j.arr.2023.101979_bib85","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1080\/13543784.2020.1764534","article-title":"Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson's disease","volume":"29","author":"Glotfelty","year":"2020","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.arr.2023.101979_bib86","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/jne.12138","article-title":"Protective effect of leptin and ghrelin against toxicity induced by amyloid-\u03b2 oligomers in a hypothalamic cell line","volume":"26","author":"Gomes","year":"2014","journal-title":"J. Neuroendocr."},{"key":"10.1016\/j.arr.2023.101979_bib87","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3389\/fncel.2019.00017","article-title":"The link between tau and insulin signaling: implications for Alzheimer's disease and other tauopathies","volume":"13","author":"Goncalves","year":"2019","journal-title":"Front Cell Neurosci."},{"key":"10.1016\/j.arr.2023.101979_bib88","doi-asserted-by":"crossref","first-page":"C125","DOI":"10.1152\/ajpcell.00240.2017","article-title":"Insulin transport into the brain","volume":"315","author":"Gray","year":"2018","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.arr.2023.101979_bib89","article-title":"Chronic leptin supplementation ameliorates pathology and improves cognitive performance in a transgenic mouse model of Alzheimer's disease","author":"Greco","year":"2009","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2023.101979_bib90","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3389\/fnins.2019.01112","article-title":"Glucagon-like peptide-1: a focus on neurodegenerative diseases","volume":"13","author":"Grieco","year":"2019","journal-title":"Front Neurosci."},{"key":"10.1016\/j.arr.2023.101979_bib91","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3233\/JAD-180433","article-title":"Neuroprotective effects of amylin analogues on Alzheimer's disease pathogenesis and cognition","volume":"66","author":"Grizzanti","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2023.101979_bib92","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.neuropharm.2011.01.033","article-title":"Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes","volume":"60","author":"Gupta","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.arr.2023.101979_bib93","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3233\/JAD-143090","article-title":"The GLP-1 receptor agonist liraglutide improves memory function and increases hippocampal CA1 neuronal numbers in a senescence-accelerated mouse model of Alzheimer's disease","volume":"46","author":"Hansen","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2023.101979_bib94","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.brainres.2015.12.052","article-title":"The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy","volume":"1634","author":"Hansen","year":"2016","journal-title":"Brain Res"},{"key":"10.1016\/j.arr.2023.101979_bib95","doi-asserted-by":"crossref","first-page":"592","DOI":"10.2174\/156720511796391935","article-title":"Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies","volume":"8","author":"Harrington","year":"2011","journal-title":"Curr. Alzheimer Res"},{"key":"10.1016\/j.arr.2023.101979_bib96","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/aps.2014.80","article-title":"Protein tyrosine phosphatases as potential therapeutic targets","volume":"35","author":"He","year":"2014","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.arr.2023.101979_bib97","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/atv.0000615456.97862.30","article-title":"Endothelial GLP-1 (Glucagon-Like Peptide-1) receptor mediates cardiovascular protection by liraglutide in mice with experimental arterial hypertension","volume":"40","author":"Helmstadter","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.arr.2023.101979_bib98","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1093\/brain\/awh452","article-title":"Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice","volume":"128","author":"Heneka","year":"2005","journal-title":"Brain"},{"key":"10.1016\/j.arr.2023.101979_bib99","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13195-020-00607-4","article-title":"Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer's disease and type 2 diabetes","volume":"12","author":"Hierro-Bujalance","year":"2020","journal-title":"Alzheimers Res Ther."},{"key":"10.1016\/j.arr.2023.101979_bib100","first-page":"259","article-title":"High prevalence of undiagnosed insulin resistance in non-diabetic subjects with Parkinson's disease","volume":"8","author":"Hogg","year":"2018","journal-title":"J. Park. Dis."},{"key":"10.1016\/j.arr.2023.101979_bib101","first-page":"784","article-title":"Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care","volume":"26","author":"Hollander","year":"2003"},{"key":"10.1016\/j.arr.2023.101979_bib102","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3389\/fnagi.2019.00088","article-title":"Insulin Signaling Impairment in the Brain as a Risk Factor in Alzheimer's Disease","volume":"11","author":"Holscher","year":"2019","journal-title":"Front Aging Neurosci."},{"key":"10.1016\/j.arr.2023.101979_bib103","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/13543784.2020.1738383","article-title":"Brain insulin resistance: role in neurodegenerative disease and potential for targeting","volume":"29","author":"Holscher","year":"2020","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.arr.2023.101979_bib104","first-page":"9","article-title":"Insulin resistance promotes Parkinson's disease through aberrant expression of alpha-synuclein, mitochondrial dysfunction, and deregulation of the polo-like kinase 2 signaling","author":"Hong","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.arr.2023.101979_bib105","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejphar.2004.02.049","article-title":"Glucose metabolism and insulin receptor signal transduction in Alzheimer disease","volume":"490","author":"Hoyer","year":"2004","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.arr.2023.101979_bib106","doi-asserted-by":"crossref","first-page":"842","DOI":"10.2337\/dc06-2011","article-title":"Type 2 diabetes and the risk of Parkinson's disease","volume":"30","author":"Hu","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.arr.2023.101979_bib107","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"NewEngl. J. Med."},{"key":"10.1016\/j.arr.2023.101979_bib108","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1080\/13543776.2019.1655542","article-title":"Protein tyrosine phosphatase 1B (PTP1B) inhibitors as potential anti-diabetes agents: patent review (2015-2018)","volume":"29","author":"Hussain","year":"2019","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.arr.2023.101979_bib109","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1007\/s10787-022-00973-5","article-title":"Dapagliflozin as an autophagic enhancer via LKB1\/AMPK\/SIRT1 pathway in ovariectomized\/D-galactose Alzheimer's rat model","volume":"30","author":"Ibrahim","year":"2022","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.arr.2023.101979_bib110","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/j.1532-5415.2012.03916.x","article-title":"Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: a population-based case-control study","volume":"60","author":"Imfeld","year":"2012","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.arr.2023.101979_bib111","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/archneurol.2007.29","article-title":"Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE \u03b54: the cardiovascular health study cognition study","volume":"65","author":"Irie","year":"2008","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.arr.2023.101979_bib112","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.diabres.2016.12.010","article-title":"The effects of sitagliptin, a DPP-4 inhibitor, on cognitive functions in elderly diabetic patients with or without Alzheimer\u2019s disease","volume":"123","author":"Isik","year":"2017","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.arr.2023.101979_bib113","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/ana.23956","article-title":"Amylin deposition in the brain: a second amyloid in Alzheimer disease?","volume":"74","author":"Jackson","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.arr.2023.101979_bib114","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.neuropharm.2017.02.013","article-title":"A novel GLP-1\/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease","volume":"117","author":"Jalewa","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.arr.2023.101979_bib115","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s11011-020-00538-x","article-title":"The effects simultaneous inhibition of dipeptidyl peptidase-4 and P2X7 purinoceptors in an in vivo Parkinson's disease model","volume":"35","author":"Jamali-Raeufy","year":"2020","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.arr.2023.101979_bib116","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.arr.2023.101979_bib117","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ajpath.2010.11.022","article-title":"Actions of beta-amyloid protein on human neurons are expressed through the amylin receptor","volume":"178","author":"Jhamandas","year":"2011","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.arr.2023.101979_bib118","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1515\/revneuro-2015-0021","article-title":"Neuroprotective effects of glucose-dependent insulinotropic polypeptide in Alzheimer's disease","volume":"27","author":"Ji","year":"2016","journal-title":"Rev. Neurosci."},{"key":"10.1016\/j.arr.2023.101979_bib119","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2015.09.035","article-title":"A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF","volume":"1634","author":"Ji","year":"2016","journal-title":"Brain Res."},{"key":"10.1016\/j.arr.2023.101979_bib120","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1096\/fj.14-262048","article-title":"Dysfunctionally phosphorylated type 1 insulin receptor substrate in neural-derived blood exosomes of preclinical Alzheimer's disease","volume":"29","author":"Kapogiannis","year":"2015","journal-title":"FASEB J."},{"key":"10.1016\/j.arr.2023.101979_bib121","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1007\/s00125-006-0409-y","article-title":"Low cerebrospinal fluid insulin levels in obese humans","volume":"49","author":"Kern","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.arr.2023.101979_bib122","doi-asserted-by":"crossref","first-page":"21830","DOI":"10.1073\/pnas.0912793107","article-title":"Biguanide metformin acts on tau phosphorylation via mTOR\/protein phosphatase 2A (PP2A) signaling","volume":"107","author":"Kickstein","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.arr.2023.101979_bib123","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1677\/JOE-09-0132","article-title":"Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease","volume":"202","author":"Kim","year":"2009","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.arr.2023.101979_bib124","doi-asserted-by":"crossref","first-page":"10644","DOI":"10.1038\/s41598-018-28849-1","article-title":"Down-regulation of vascular GLP-1 receptor expression in human subjects with obesity","volume":"8","author":"Kimura","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.arr.2023.101979_bib125","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1006\/bbrc.1998.9981","article-title":"Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-gamma in Alzheimer's disease brains","volume":"254","author":"Kitamura","year":"1999","journal-title":"Biochem. Biophys. Res Commun."},{"key":"10.1016\/j.arr.2023.101979_bib126","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/alz.12213","article-title":"Failure to demonstrate efficacy of aducanumab: an analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019","volume":"17","author":"Knopman","year":"2021","journal-title":"Alzheimer'S. Dement."},{"key":"10.1016\/j.arr.2023.101979_bib127","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/WAD.0000000000000202","article-title":"Effects of the insulin sensitizer metformin in Alzheimer disease: pilot data from a randomized placebo-controlled crossover study","volume":"31","author":"Koenig","year":"2017","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.arr.2023.101979_bib128","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/cns.12404","article-title":"DPP-4 inhibitor linagliptin attenuates abeta-induced cytotoxicity through activation of AMPK in neuronal cells","volume":"21","author":"Kornelius","year":"2015","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.arr.2023.101979_bib129","doi-asserted-by":"crossref","first-page":"6074","DOI":"10.1007\/s12035-016-0125-7","article-title":"Linagliptin, a dipeptidyl peptidase-4 inhibitor, mitigates cognitive deficits and pathology in the 3xTg-AD mouse model of Alzheimer's disease","volume":"54","author":"Kosaraju","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.arr.2023.101979_bib130","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.tips.2017.10.008","article-title":"Insulin-degrading enzyme in the fight against Alzheimer's disease","volume":"39","author":"Kurochkin","year":"2018","journal-title":"Trends Pharm. Sci."},{"key":"10.1016\/j.arr.2023.101979_bib131","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/emmm.201100177","article-title":"Insulin biosynthesis in neuronal progenitors derived from adult hippocampus and the olfactory bulb","volume":"3","author":"Kuwabara","year":"2011","journal-title":"EMBO Mol. Med"},{"key":"10.1016\/j.arr.2023.101979_bib132","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2174\/156720507780362092","article-title":"Therapeutic use of agonists of the nuclear receptor PPARgamma in Alzheimer's disease","volume":"4","author":"Landreth","year":"2007","journal-title":"Curr. Alzheimer Res"},{"key":"10.1016\/j.arr.2023.101979_bib133","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/oxfordjournals.aje.a009106","article-title":"Risk of dementia among persons with diabetes mellitus: a population-based cohort study","volume":"145","author":"Leibson","year":"1997","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.arr.2023.101979_bib134","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hipo.22837","article-title":"A novel GLP-1\/GIP\/Gcg triagonist reduces cognitive deficits and pathology in the 3xTg mouse model of Alzheimer's disease","volume":"28","author":"Li","year":"2018","journal-title":"Hippocampus"},{"key":"10.1016\/j.arr.2023.101979_bib135","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108042","article-title":"A GLP-1\/GIP\/Gcg receptor triagonist improves memory behavior, as well as synaptic transmission, neuronal excitability and Ca2+ homeostasis in 3xTg-AD mice","volume":"170","author":"Li","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.arr.2023.101979_bib136","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117824","article-title":"Neuroprotection of GLP-1\/GIP receptor agonist via inhibition of mitochondrial stress by AKT\/JNK pathway in a Parkinson's disease model","volume":"256","author":"Li","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.arr.2023.101979_bib137","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2147\/CIA.S74042","article-title":"Link between type 2 diabetes and Alzheimer's disease: from epidemiology to mechanism and treatment","volume":"10","author":"Li","year":"2015","journal-title":"Clin. Inter. Aging"},{"key":"10.1016\/j.arr.2023.101979_bib138","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1073\/pnas.0806720106","article-title":"GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism","volume":"106","author":"Li","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.arr.2023.101979_bib139","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.neuropharm.2015.10.002","article-title":"Neuroprotective effects of a GIP analogue in the MPTP Parkinson's disease mouse model","volume":"101","author":"Li","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.arr.2023.101979_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2019.113113","article-title":"Neurotrophic and neuroprotective effects of a monomeric GLP-1\/GIP\/Gcg receptor triagonist in cellular and rodent models of mild traumatic brain injury","volume":"324","author":"Li","year":"2020","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.arr.2023.101979_bib141","doi-asserted-by":"crossref","DOI":"10.3390\/antiox10121935","article-title":"Two birds one stone: the neuroprotective effect of antidiabetic agents on Parkinson disease-focus on sodium-glucose cotransporter 2 (SGLT2) inhibitors","author":"Lin","year":"2021","journal-title":"Antioxidants"},{"key":"10.1016\/j.arr.2023.101979_bib142","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jns.2017.08.3235","article-title":"Sodium butyrate exerts protective effect against Parkinson's disease in mice via stimulation of glucagon like peptide-1","volume":"381","author":"Liu","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.arr.2023.101979_bib143","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/2315106","article-title":"Metformin ameliorates abeta pathology by insulin-degrading enzyme in a transgenic mouse model of Alzheimer's disease","volume":"2020","author":"Lu","year":"2020","journal-title":"Oxid. Med Cell Longev."},{"key":"10.1016\/j.arr.2023.101979_bib144","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/aje\/154.7.635","article-title":"Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort","volume":"154","author":"Luchsinger","year":"2001","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.arr.2023.101979_bib145","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3233\/JAD-150493","article-title":"Metformin in amnestic mild cognitive impairment: results of a pilot randomized placebo controlled clinical trial","volume":"51","author":"Luchsinger","year":"2016","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2023.101979_bib146","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ejim.2014.03.005","article-title":"Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities","volume":"25","author":"Lund","year":"2014","journal-title":"Eur. J. Intern Med"},{"key":"10.1016\/j.arr.2023.101979_bib147","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.2231","article-title":"The GLP-1\/GIP dual-receptor agonist DA5-CH inhibits the NF-kappaB inflammatory pathway in the MPTP mouse model of Parkinson's disease more effectively than the GLP-1 single-receptor agonist NLY01","author":"Lv","year":"2021","journal-title":"Brain Behav."},{"key":"10.1016\/j.arr.2023.101979_bib148","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1586\/14789450.2015.1104251","article-title":"Hyperamylinemia as a risk factor for accelerated cognitive decline in diabetes","volume":"12","author":"Ly","year":"2015","journal-title":"Expert Rev. Proteom."},{"key":"10.1016\/j.arr.2023.101979_bib149","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000064928","article-title":"Diabetes mellitus and the risk of dementia, Alzheimer\u2019s disease and vascular cognitive impairment in the canadian study of health and aging","volume":"14","author":"MacKnight","year":"2002","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"10.1016\/j.arr.2023.101979_bib150","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.660942","article-title":"Attenuated postprandial GLP-1 response in Parkinson's disease","volume":"15","author":"Manfready","year":"2021","journal-title":"Front Neurosci."},{"key":"10.1016\/j.arr.2023.101979_bib151","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.arr.2023.101979_bib152","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.arr.2023.101979_bib153","doi-asserted-by":"crossref","DOI":"10.1177\/1533317520953041","article-title":"The Dual GLP-1\/GIP receptor agonist DA4-JC shows superior protective properties compared to the GLP-1 analogue liraglutide in the APP\/PS1 mouse model of Alzheimer's disease","volume":"35","author":"Maskery","year":"2020","journal-title":"Am. J. Alzheimers Dis. Other Demen"},{"key":"10.1016\/j.arr.2023.101979_bib154","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.3390\/ijms20174092","article-title":"The effects of dual GLP-1\/GIP receptor agonism on glucagon secretion-a review","volume":"20","author":"Mathiesen","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.arr.2023.101979_bib155","first-page":"4","article-title":"Release of insulin produced by the choroid plexis is regulated by serotonergic signaling","author":"Mazucanti","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.arr.2023.101979_bib156","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.neuropharm.2013.08.005","article-title":"Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP\/PS1 mice, a model of Alzheimer's disease","author":"McClean","year":"2014","journal-title":"Neuropharmacol. 76 Pt A"},{"key":"10.1016\/j.arr.2023.101979_bib157","doi-asserted-by":"crossref","first-page":"6587","DOI":"10.1523\/JNEUROSCI.0529-11.2011","article-title":"The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease","volume":"31","author":"McClean","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.arr.2023.101979_bib158","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0083-6729(08)00615-8","article-title":"Glucose-dependent insulinotropic polypeptide (Gastric Inhibitory Polypeptide; GIP)","volume":"80","author":"McIntosh","year":"2009","journal-title":"Vitam. Horm."},{"key":"10.1016\/j.arr.2023.101979_bib159","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.cmet.2012.10.019","article-title":"Hyperinsulinemia drives diet-induced obesity independently of brain insulin production","volume":"16","author":"Mehran","year":"2012","journal-title":"Cell Metab."},{"key":"10.1016\/j.arr.2023.101979_bib160","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus","volume":"8","author":"Meier","year":"2012","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.arr.2023.101979_bib161","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.1016\/j.dsx.2016.01.021","article-title":"Shared links between type 2 diabetes mellitus and Alzheimer's disease: a review","volume":"10","author":"Mittal","year":"2016","journal-title":"Diabetes Metab. Syndr."},{"key":"10.1016\/j.arr.2023.101979_bib162","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.2337\/dc13-0229","article-title":"Increased risk of cognitive impairment in patients with diabetes is associated with metformin","volume":"36","author":"Moore","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.arr.2023.101979_bib163","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2022.110002","article-title":"Empagliflozin alleviates endoplasmic reticulum stress and augments autophagy in rotenone-induced Parkinson's disease in rats: Targeting the GRP78\/PERK\/eIF2\u03b1\/CHOP pathway and miR-211-5p","volume":"362","author":"Motawi","year":"2022","journal-title":"Chem. Biol. Inter."},{"key":"10.1016\/j.arr.2023.101979_bib164","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.121258","article-title":"Empagliflozin enhances neuroplasticity in rotenone-induced parkinsonism: Role of BDNF, CREB and Npas4","volume":"312","author":"Mousa","year":"2023","journal-title":"Life Sci."},{"key":"10.1016\/j.arr.2023.101979_bib165","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1038\/s41598-020-60664-5","article-title":"Amylin and pramlintide modulate \u03b3-secretase level and APP processing in lipid rafts","volume":"10","author":"Mousa","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.arr.2023.101979_bib166","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"Muller","year":"2019","journal-title":"Mol. Metab."},{"key":"10.1016\/j.arr.2023.101979_bib167","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/hbm.23494","article-title":"Exosomal biomarkers of brain insulin resistance associated with regional atrophy in Alzheimer's disease","volume":"38","author":"Mullins","year":"2017","journal-title":"Hum. Brain Mapp."},{"key":"10.1016\/j.arr.2023.101979_bib168","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2174\/1567205016666190913155950","article-title":"A pilot study of exenatide actions in Alzheimer's disease","volume":"16","author":"Mullins","year":"2019","journal-title":"Curr. Alzheimer Res"},{"key":"10.1016\/j.arr.2023.101979_bib169","article-title":"GLP-1 receptor agonists for Parkinson's disease","volume":"7","author":"Mulvaney","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.arr.2023.101979_bib170","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3233\/JAD-180578","article-title":"Extracellular vesicle biomarkers track cognitive changes following intranasal insulin in Alzheimer's disease","volume":"69","author":"Mustapic","year":"2019","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2023.101979_bib171","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/dom.12591","article-title":"Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors","volume":"18","author":"Nauck","year":"2016","journal-title":"Diabetes, Obes. Metab."},{"key":"10.1016\/j.arr.2023.101979_bib172","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1021\/acschemneuro.7b00434","article-title":"Pharmacokinetics of intranasal versus subcutaneous insulin in the mouse","volume":"9","author":"Nedelcovych","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.arr.2023.101979_bib173","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1021\/np400533h","article-title":"Protein tyrosine phosphatase 1B (PTP1B) inhibitors from morinda citrifolia (noni) and their insulin mimetic activity","volume":"76","author":"Nguyen","year":"2013","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.arr.2023.101979_bib174","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214364","article-title":"Safety and preliminary efficacy of intranasal insulin for cognitive impairment in Parkinson disease and multiple system atrophy: a double-blinded placebo-controlled pilot study","volume":"14","author":"Novak","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.arr.2023.101979_bib175","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/978-981-13-3540-2_11","article-title":"Therapeutic strategies for Alzheimer's disease in the view of diabetes mellitus","volume":"1128","author":"Ohyagi","year":"2019","journal-title":"Adv. Exp. Med Biol."},{"key":"10.1016\/j.arr.2023.101979_bib176","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.bbi.2017.12.009","article-title":"Metformin treatment prevents amyloid plaque deposition and memory impairment in APP\/PS1 mice","volume":"69","author":"Ou","year":"2018","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.arr.2023.101979_bib177","first-page":"22","article-title":"Liraglutide has anti-inflammatory and anti-amyloid properties in streptozotocin-induced and 5xFAD mouse models of Alzheimer's disease","author":"Paladugu","year":"2021","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.arr.2023.101979_bib178","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3233\/JAD-180584","article-title":"The novel DA-CH3 dual incretin restores endoplasmic reticulum stress and autophagy impairments to attenuate Alzheimer-like pathology and cognitive decrements in the APPSWE\/PS1\u0394E9 mouse model","volume":"66","author":"Panagaki","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2023.101979_bib179","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.neuroscience.2014.07.046","article-title":"Neuroprotective effect of metformin in MPTP-induced Parkinson's disease in mice","volume":"277","author":"Patil","year":"2014","journal-title":"Neuroscience"},{"key":"10.1016\/j.arr.2023.101979_bib180","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.2337\/diabetes.51.4.1256","article-title":"Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the honolulu-Asia Aging Study","volume":"51","author":"Peila","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.arr.2023.101979_bib181","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2020-001370","article-title":"Association between metformin and neurodegenerative diseases of observational studies: systematic review and meta-analysis","volume":"8","author":"Ping","year":"2020","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"10.1016\/j.arr.2023.101979_bib182","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1080\/07853890.2016.1197416","article-title":"Insulin-degrading enzyme: new therapeutic target for diabetes and Alzheimer's disease?","volume":"48","author":"Pivovarova","year":"2016","journal-title":"Ann. Med"},{"key":"10.1016\/j.arr.2023.101979_bib183","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/cns.12866","article-title":"Insulin receptor in the brain: Mechanisms of activation and the role in the CNS pathology and treatment","volume":"24","author":"Pomytkin","year":"2018","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.arr.2023.101979_bib184","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/jcb.25376","article-title":"The neuroprotective role of insulin against MPP(+) -induced Parkinson's Disease in differentiated SH-SY5Y Cells","volume":"117","author":"Ramalingam","year":"2016","journal-title":"J. Cell Biochem"},{"key":"10.1016\/j.arr.2023.101979_bib185","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1016\/j.neurobiolaging.2009.12.005","article-title":"Insulin resistance and hippocampal volume in women at risk for Alzheimer's disease","volume":"32","author":"Rasgon","year":"2011","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.arr.2023.101979_bib186","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/15209150252924094","article-title":"Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes","volume":"4","author":"Ratner","year":"2002","journal-title":"Diabetes Technol. Ther."},{"key":"10.1016\/j.arr.2023.101979_bib187","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/j.1464-5491.2004.01319.x","article-title":"Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial","volume":"21","author":"Ratner","year":"2004","journal-title":"Diabet. Med"},{"key":"10.1016\/j.arr.2023.101979_bib188","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.neurobiolaging.2005.03.016","article-title":"Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype","volume":"27","author":"Reger","year":"2006","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.arr.2023.101979_bib189","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3233\/JAD-2008-13309","article-title":"Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults","volume":"13","author":"Reger","year":"2008","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2023.101979_bib190","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1212\/01.WNL.0000265401.62434.36","article-title":"Intranasal insulin improves cognition and modulates beta-amyloid in early AD","volume":"70","author":"Reger","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2023.101979_bib191","first-page":"5","article-title":"Therapeutic advantages of dual targeting of PPAR-delta and PPAR-gamma in an experimental model of sporadic Alzheimer's disease","author":"Reich","year":"2018","journal-title":"J. Park. Dis. Alzheimers Dis."},{"key":"10.1016\/j.arr.2023.101979_bib192","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00125-017-4342-z","article-title":"The mechanisms of action of metformin","volume":"60","author":"Rena","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.arr.2023.101979_bib193","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1113\/JP276149","article-title":"Insulin transport across the blood-brain barrier can occur independently of the insulin receptor","volume":"596","author":"Rhea","year":"2018","journal-title":"J. Physiol."},{"key":"10.1016\/j.arr.2023.101979_bib194","first-page":"10","article-title":"Insulin resistance in peripheral tissues and the brain: a tale of two sites","author":"Rhea","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.arr.2023.101979_bib195","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1523\/JNEUROSCI.2120-19.2019","article-title":"Neuronal protein tyrosine phosphatase 1B hastens amyloid \u03b2-associated Alzheimer's disease in mice","volume":"40","author":"Ricke","year":"2020","journal-title":"J. Neurosci."},{"key":"10.1016\/j.arr.2023.101979_bib196","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.2337\/dc07-0589","article-title":"Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin","volume":"30","author":"Riddle","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.arr.2023.101979_bib197","first-page":"246","article-title":"Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease","volume":"6","author":"Risner","year":"2006","journal-title":"Pharm. J."},{"key":"10.1016\/j.arr.2023.101979_bib198","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1093\/gerona\/glu032","article-title":"Dipeptidyl peptidase-4 inhibitors have protective effect on cognitive impairment in aged diabetic patients with mild cognitive impairment","volume":"69","author":"Rizzo","year":"2014","journal-title":"J. Gerontol.: Ser. A"},{"key":"10.1016\/j.arr.2023.101979_bib199","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s12630-021-01969-5","article-title":"Intranasal administration of 40 and 80 units of insulin does not cause hypoglycemia during cardiac surgery: a randomized controlled trial","volume":"68","author":"Roque","year":"2021","journal-title":"Can. J. Anesth. \/J. Can. D. 'Anesth."},{"key":"10.1016\/j.arr.2023.101979_bib200","first-page":"9","article-title":"The therapeutic potential of metformin in neurodegenerative diseases","author":"Rotermund","year":"2018","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.arr.2023.101979_bib201","doi-asserted-by":"crossref","first-page":"5715","DOI":"10.1007\/s12035-017-0752-7","article-title":"Metformin inhibits the development of L-DOPA-induced dyskinesia in a murine model of Parkinson's disease","volume":"55","author":"Ryu","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.arr.2023.101979_bib202","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.neures.2019.12.017","article-title":"Neuroprotective effect of metformin on dopaminergic neurodegeneration and alpha-synuclein aggregation in C. elegans model of Parkinson's disease","volume":"162","author":"Saewanee","year":"2021","journal-title":"Neurosci. Res"},{"key":"10.1016\/j.arr.2023.101979_bib203","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117861","article-title":"Metformin loaded phosphatidylserine nanoliposomes improve memory deficit and reduce neuroinflammation in streptozotocin-induced Alzheimer's disease model","volume":"255","author":"Saffari","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.arr.2023.101979_bib204","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006379","article-title":"Proteolytic degradation of amyloid \u03b2-protein","volume":"2","author":"Saido","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.arr.2023.101979_bib205","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114187","article-title":"Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer's and Parkinson's disease therapeutics","volume":"180","author":"Salameh","year":"2020","journal-title":"Biochem Pharm."},{"key":"10.1016\/j.arr.2023.101979_bib206","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.parkreldis.2020.08.018","article-title":"Peripheral insulin and amylin levels in Parkinson's disease","volume":"79","author":"Sanchez-Gomez","year":"2020","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.arr.2023.101979_bib207","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0126804","article-title":"The brain response to peripheral insulin declines with age: a contribution of the blood-brain barrier?","volume":"10","author":"Sartorius","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.arr.2023.101979_bib208","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.neurobiolaging.2009.10.009","article-title":"Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease","volume":"32","author":"Sato","year":"2011","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.arr.2023.101979_bib209","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3389\/fendo.2018.00649","article-title":"Future perspectives on GLP-1 receptor agonists and GLP-1\/glucagon receptor co-agonists in the treatment of NAFLD","volume":"9","author":"Seghieri","year":"2018","journal-title":"Front Endocrinol."},{"key":"10.1016\/j.arr.2023.101979_bib210","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.2040-1124.2010.00022.x","article-title":"GIP and GLP-1, the two incretin hormones: similarities and differences","volume":"1","author":"Seino","year":"2010","journal-title":"J. Diabetes Invest."},{"key":"10.1016\/j.arr.2023.101979_bib211","doi-asserted-by":"crossref","first-page":"12531","DOI":"10.1038\/srep12531","article-title":"Insulin-degrading enzyme prevents alpha-synuclein fibril formation in a nonproteolytical manner","volume":"5","author":"Sharma","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.arr.2023.101979_bib212","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2021.135754","article-title":"Therapies modulating insulin resistance in Parkinson's disease: a cross talk","volume":"749","author":"Sharma","year":"2021","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.arr.2023.101979_bib213","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-024954","article-title":"Effect of metformin on neurodegenerative disease among elderly adult US veterans with type 2 diabetes mellitus","volume":"9","author":"Shi","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.arr.2023.101979_bib214","doi-asserted-by":"crossref","DOI":"10.1177\/14791641221098168","article-title":"The association between sodium-glucose cotransporter 2 inhibitors and incident dementia: a nationwide population-based longitudinal cohort study","volume":"19","author":"Siao","year":"2022","journal-title":"Diab Vasc. Dis. Res"},{"key":"10.1016\/j.arr.2023.101979_bib215","first-page":"105","article-title":"Metformin and risk of Alzheimer's disease among community-dwelling people with diabetes: a national case-control study","author":"Sluggett","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.arr.2023.101979_bib216","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.neuint.2019.04.010","article-title":"GLP-1: molecular mechanisms and outcomes of a complex signaling system","volume":"128","author":"Smith","year":"2019","journal-title":"Neurochem Int."},{"key":"10.1016\/j.arr.2023.101979_bib217","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1038\/s41598-018-22434-2","article-title":"Identification of insulin receptor splice variant B in neurons by in situ detection in human brain samples","volume":"8","author":"Spencer","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.arr.2023.101979_bib218","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ejcb.2017.03.004","article-title":"Incretin hormones regulate microglia oxidative stress, survival and expression of trophic factors","volume":"96","author":"Spielman","year":"2017","journal-title":"Eur. J. Cell Biol."},{"key":"10.1016\/j.arr.2023.101979_bib219","first-page":"9","article-title":"Recent developments in the treatment of Parkinson's disease","author":"Stoker","year":"2020","journal-title":"F1000Res"},{"key":"10.1016\/j.arr.2023.101979_bib220","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1002\/mds.26734","article-title":"Reduced incidence of Parkinson's disease after dipeptidyl peptidase-4 inhibitors-a nationwide case-control study","volume":"31","author":"Svenningsson","year":"2016","journal-title":"Mov. Disord."},{"key":"10.1016\/j.arr.2023.101979_bib221","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.brainres.2017.10.012","article-title":"Neuroprotective effects of a triple GLP-1\/GIP\/glucagon receptor agonist in the APP\/PS1 transgenic mouse model of Alzheimer's disease","volume":"1678","author":"Tai","year":"2018","journal-title":"Brain Res."},{"key":"10.1016\/j.arr.2023.101979_bib222","doi-asserted-by":"crossref","DOI":"10.1016\/j.jalz.2011.09.137","article-title":"P4-441: the diabetes drug liraglutide ameliorates insulin resistance in the hippocampal formation of Alzheimer's disease (AD) cases","volume":"7","author":"Talbot","year":"2011","journal-title":"Alzheimer'S. Dement."},{"key":"10.1016\/j.arr.2023.101979_bib223","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1172\/JCI59903","article-title":"Demonstrated brain insulin resistance in Alzheimer\u2019s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline","volume":"122","author":"Talbot","year":"2012","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.arr.2023.101979_bib224","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1172\/JCI59903","article-title":"Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline","volume":"122","author":"Talbot","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.arr.2023.101979_bib225","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.expneurol.2016.11.005","article-title":"Novel GLP-1R\/GIPR co-agonist \"twincretin\" is neuroprotective in cell and rodent models of mild traumatic brain injury","volume":"288","author":"Tamargo","year":"2017","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.arr.2023.101979_bib226","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1517\/13543776.2014.947268","article-title":"PTP1B inhibitors for type 2 diabetes treatment: a patent review (2011 - 2014)","volume":"24","author":"Tamrakar","year":"2014","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.arr.2023.101979_bib227","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3233\/JAD-170948","article-title":"Pramlintide: the effects of a single drug injection on blood phosphatidylcholine profile for Alzheimer's disease","volume":"62","author":"Tao","year":"2018","journal-title":"J. Alzheimer's. Dis.: JAD"},{"key":"10.1016\/j.arr.2023.101979_bib228","first-page":"25","article-title":"Shortcut approaches to substance delivery into the brain based on intranasal administration using nanodelivery strategies for insulin","author":"Tashima","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.arr.2023.101979_bib229","first-page":"20","article-title":"Novel approaches for the treatment of Alzheimer's and Parkinson's disease","author":"Van Bulck","year":"2019","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.arr.2023.101979_bib230","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2022","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.arr.2023.101979_bib231","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.nbd.2015.04.008","article-title":"The role of type 2 diabetes in neurodegeneration","volume":"84","author":"Verdile","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.arr.2023.101979_bib232","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40290-020-00374-5","article-title":"Repurposing GLP-1 receptor agonists for Parkinson's disease: current evidence and future opportunities","volume":"35","author":"Victorino","year":"2021","journal-title":"Pharm. Med"},{"key":"10.1016\/j.arr.2023.101979_bib233","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2017.00007","article-title":"Protein tyrosine phosphatase 1B (PTP1B): a potential target for Alzheimer's therapy?","volume":"9","author":"Vieira","year":"2017","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.arr.2023.101979_bib234","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.neuropharm.2017.11.014","article-title":"Connecting Alzheimer's disease to diabetes: underlying mechanisms and potential therapeutic targets","volume":"136","author":"Vieira","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.arr.2023.101979_bib235","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1210\/jcem-64-1-190","article-title":"Cerebrospinal fluid insulin levels increase during intravenous insulin infusions in man","volume":"64","author":"Wallum","year":"1987","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.arr.2023.101979_bib236","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1080\/15376516.2020.1741053","article-title":"Protective effect of metformin against rotenone-induced parkinsonism in mice","volume":"30","author":"Wang","year":"2020","journal-title":"Toxicol. Mech. Methods"},{"key":"10.1016\/j.arr.2023.101979_bib237","first-page":"17","article-title":"Antidiabetic agents for treatment of Parkinson's disease: a meta-analysis","author":"Wang","year":"2020","journal-title":"Int J. Environ. Res Public Health"},{"key":"10.1016\/j.arr.2023.101979_bib238","first-page":"950","article-title":"Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study","volume":"13","author":"Watson","year":"2005","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.arr.2023.101979_bib239","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.bbr.2018.08.006","article-title":"Neural correlates of liraglutide effects in persons at risk for Alzheimer's disease","volume":"356","author":"Watson","year":"2019","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.arr.2023.101979_bib240","doi-asserted-by":"crossref","first-page":"724","DOI":"10.2337\/diacare.25.4.724","article-title":"A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes","volume":"25","author":"Whitehouse","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.arr.2023.101979_bib241","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1001\/jamaneurol.2015.0613","article-title":"Association of insulin resistance with cerebral glucose uptake in late middle-aged adults at risk for Alzheimer disease","author":"Willette","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.arr.2023.101979_bib242","doi-asserted-by":"crossref","DOI":"10.2337\/db19-1810-P","article-title":"1810-P: effect of HM15211, a novel long-acting GLP-1\/GIP\/glucagon triple agonist in the neurodegenerative disease models","volume":"68","author":"WONKI","year":"2019","journal-title":"Diabetes"},{"key":"10.1016\/j.arr.2023.101979_bib243","unstructured":"World Health Organisation, 2020. Dementia,"},{"key":"10.1016\/j.arr.2023.101979_bib244","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1002\/alz.12161","article-title":"Relationships between memory decline and the use of metformin or DPP4 inhibitors in people with type 2 diabetes with normal cognition or Alzheimer's disease, and the role APOE carrier status","volume":"16","author":"Wu","year":"2020","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.arr.2023.101979_bib245","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2337\/dc22-1705","article-title":"Association of sodium\u2013glucose cotransporter 2 inhibitors with time to dementia: a population-based cohort study","volume":"46","author":"Wu","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.arr.2023.101979_bib246","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114578","article-title":"GLP-1 improves the neuronal supportive ability of astrocytes in Alzheimer's disease by regulating mitochondrial dysfunction via the cAMP\/PKA pathway","volume":"188","author":"Xie","year":"2021","journal-title":"Biochem. Pharm."},{"key":"10.1016\/j.arr.2023.101979_bib247","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.neuroscience.2018.06.018","article-title":"Insulin-signaling pathway regulates the degradation of amyloid beta-protein via astrocytes","volume":"385","author":"Yamamoto","year":"2018","journal-title":"Neuroscience"},{"key":"10.1016\/j.arr.2023.101979_bib248","doi-asserted-by":"crossref","first-page":"7504","DOI":"10.1523\/JNEUROSCI.23-20-07504.2003","article-title":"Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease","volume":"23","author":"Yan","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.arr.2023.101979_bib249","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.mcn.2015.10.005","article-title":"Exendin-4 reduces tau hyperphosphorylation in type 2 diabetic rats via increasing brain insulin level","volume":"70","author":"Yang","year":"2016","journal-title":"Mol. Cell Neurosci."},{"key":"10.1016\/j.arr.2023.101979_bib250","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00401-014-1328-5","article-title":"Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimer's disease and tauopathies","volume":"128","author":"Yarchoan","year":"2014","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.arr.2023.101979_bib251","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118645","article-title":"GLP-1 mimetics and cognition","volume":"264","author":"Yaribeygi","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.arr.2023.101979_bib252","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2022.912995","article-title":"Mouse models of Alzheimer's disease","volume":"15","author":"Yokoyama","year":"2022","journal-title":"Front Mol. Neurosci."},{"key":"10.1016\/j.arr.2023.101979_bib253","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejphar.2017.06.029","article-title":"A novel GLP-1\/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease","volume":"812","author":"Yuan","year":"2017","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.arr.2023.101979_bib254","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003549","article-title":"Risk of Parkinson disease in diabetes mellitus: an updated meta-analysis of population-based cohort studies","volume":"95","author":"Yue","year":"2016","journal-title":"Medicine"},{"key":"10.1016\/j.arr.2023.101979_bib255","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/s41591-018-0051-5","article-title":"Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease","volume":"24","author":"Yun","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.arr.2023.101979_bib256","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.npep.2018.07.003","article-title":"Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model","volume":"71","author":"Zhang","year":"2018","journal-title":"Neuropeptides"},{"key":"10.1016\/j.arr.2023.101979_bib257","first-page":"523","article-title":"The novel dual GLP-1\/GIP receptor agonist DA-CH5 is superior to single GLP-1 receptor agonists in the MPTP model of Parkinson's disease","volume":"10","author":"Zhang","year":"2020","journal-title":"J. Park. Dis."},{"key":"10.1016\/j.arr.2023.101979_bib258","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.bbr.2017.03.018","article-title":"GLP-1 analogue CJC-1131 prevents amyloid beta protein-induced impirments of spatial memory and synaptic plasticity in rats","volume":"326","author":"Zhang","year":"2017","journal-title":"Behav. Brain Res"},{"key":"10.1016\/j.arr.2023.101979_bib259","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.bbr.2017.11.015","article-title":"Diabetes mellitus and Alzheimer's disease: GSK-3beta as a potential link","volume":"339","author":"Zhang","year":"2018","journal-title":"Behav. Brain Res"},{"key":"10.1016\/j.arr.2023.101979_bib260","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2337\/db18-0317","article-title":"GLP-1 receptor in pancreatic \u03b1-cells regulates glucagon secretion in a glucose-dependent bidirectional manner","volume":"68","author":"Zhang","year":"2019","journal-title":"Diabetes"},{"key":"10.1016\/j.arr.2023.101979_bib261","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2019.170184","article-title":"GIP has neuroprotective effects in Alzheimer and Parkinson's disease models","volume":"125","author":"Zhang","year":"2020","journal-title":"Peptides"},{"key":"10.1016\/j.arr.2023.101979_bib262","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.neuron.2017.09.003","article-title":"Apolipoprotein E4 impairs neuronal insulin signaling by trapping insulin receptor in the endosomes","volume":"96","author":"Zhao","year":"2017","journal-title":"Neuron"},{"key":"10.1016\/j.arr.2023.101979_bib263","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejphar.2004.02.045","article-title":"Insulin and the insulin receptor in experimental models of learning and memory","volume":"490","author":"Zhao","year":"2004","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.arr.2023.101979_bib264","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101180","article-title":"GLP-1 improves the supportive ability of astrocytes to neurons by promoting aerobic glycolysis in Alzheimer's disease","volume":"47","author":"Zheng","year":"2021","journal-title":"Mol. Metab."},{"key":"10.1016\/j.arr.2023.101979_bib265","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bbrc.2019.01.103","article-title":"Dulaglutide ameliorates STZ induced AD-like impairment of learning and memory ability by modulating hyperphosphorylation of tau and NFs through GSK3beta","volume":"511","author":"Zhou","year":"2019","journal-title":"Biochem Biophys. Res Commun."},{"key":"10.1016\/j.arr.2023.101979_bib266","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/mp.2014.17","article-title":"Intraperitoneal injection of the pancreatic peptide amylin potently reduces behavioral impairment and brain amyloid pathology in murine models of Alzheimer's disease","volume":"20","author":"Zhu","year":"2015","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.arr.2023.101979_bib267","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.trci.2016.12.002","article-title":"An amylin analog used as a challenge test for Alzheimer's disease","volume":"3","author":"Zhu","year":"2017","journal-title":"Alzheimer's. Dement.: Transl. Res. Clin. Interv."}],"container-title":["Ageing Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163723001381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163723001381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T19:14:02Z","timestamp":1761592442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568163723001381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":267,"alternative-id":["S1568163723001381"],"URL":"https:\/\/doi.org\/10.1016\/j.arr.2023.101979","relation":{},"ISSN":["1568-1637"],"issn-type":[{"value":"1568-1637","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antidiabetic agents as a novel treatment for Alzheimer\u2019s and Parkinson\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Ageing Research Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arr.2023.101979","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101979"}}